Prostaglandin E-major urinary metabolite as a noninvasive surrogate marker for infantile necrotizing enterocolitis

2019 ◽  
Vol 54 (8) ◽  
pp. 1584-1589 ◽  
Author(s):  
Ken-ichiro Konishi ◽  
Mariko Yoshida ◽  
Atsushi Nakao ◽  
Keiji Tsuchiya ◽  
Chisa Tsurisawa ◽  
...  
2014 ◽  
Vol 20 (7) ◽  
pp. 1208-1216 ◽  
Author(s):  
Yoshinori Arai ◽  
Seiji Arihiro ◽  
Tomokazu Matsuura ◽  
Tomohiro Kato ◽  
Mika Matsuoka ◽  
...  

Cancers ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 768 ◽  
Author(s):  
Hironori Kawamoto ◽  
Hiromichi Hara ◽  
Jun Araya ◽  
Akihiro Ichikawa ◽  
Yu Fujita ◽  
...  

Background: Prostaglandin E2 (PGE2) is metabolized to prostaglandin E-major urinary metabolite (PGE-MUM). Enhanced cyclooxygenase-2 (COX-2) expression demonstrated in lung adenocarcinoma indicates increased PGE-MUM levels in patients with lung adenocarcinoma. Objectives: We aimed to elucidate the clinical usefulness of measuring PGE-MUM as an indicator of tumor burden in patients with lung adenocarcinoma. Methods: PGE-MUM was measured by a radioimmunoassay in control healthy volunteers (n = 124) and patients with lung adenocarcinoma (n = 54). Associations between PGE-MUM levels and clinical characteristics of the patients (including lung cancer stage and TNM factors (T: Tumor, N: Node, M: Metastasis) were examined. Results: PGE-MUM levels were significantly elevated in patients with lung adenocarcinoma. A PGE-MUM level of 14.9 μg/g∙Cr showed 70.4% sensitivity and 67.7% specificity for the diagnosis of lung adenocarcinoma. PGE-MUM levels tended to be positively correlated with cancer progression as determined by the TNM staging system. Advanced stage (stage III, stage IV, and recurrence) was significantly associated with high PGE-MUM levels by logistic regression analysis. No apparent correlation was demonstrated between PGE-MUM and carcinoma embryonic antigen (CEA) levels. Conclusions: PGE-MUM can be a promising biomarker reflecting the systemic tumor burden of lung adenocarcinoma.


2017 ◽  
Vol 64 (6) ◽  
pp. 955-961 ◽  
Author(s):  
Shin-ichiro Hagiwara ◽  
Isao Okayasu ◽  
Mutsunori Fujiwara ◽  
Masaaki Matsuura ◽  
Hiromitsu Ohnishi ◽  
...  

2020 ◽  
Vol 11 (12) ◽  
pp. e00289
Author(s):  
Natsuki Ishida ◽  
Kiichi Sugiura ◽  
Takahiro Miyazu ◽  
Satoshi Tamura ◽  
Satoshi Suzuki ◽  
...  

1987 ◽  
Vol 73 (3) ◽  
pp. 277-283 ◽  
Author(s):  
Ulrich Förstermann ◽  
Thomas J. Feuerstein

1. The rates of secretion into the circulation of prostaglandin E, prostacyclin, and thromboxane A2 were estimated in male alcoholics on the third day of withdrawal and in control subjects by measuring appropriate metabolites in urine. 2. Urinary levels of tetranor-5,11-diketo-7α-hydroxyprostane-1,16-dioic acid (the major urinary metabolite of prostaglandins E1 and E2), of 2,3-dinor-6-ketoprostaglandin F1α (the major urinary metabolite of prostacyclin) and of 6-keto-prostaglandin F1α (the stable hydrolysis product of prostacyclin) were significantly different from the normal subjects in the alcoholic group. In contrast, 2,3-dinor-thromboxane B2 (the major urinary metabolite of thromboxane A2) and thromboxane B2 (the stable hydrolysis product of thromboxane A2) were not significantly different between the groups. 3. These data suggest that the ratio of the vasodilator prostanoids prostaglandin E and prostacyclin and the vasoconstrictor prostanoid thromboxane A2 is lower than in normal subjects, in alcoholics during withdrawal. This may be one causal factor for the higher incidence of hypertension observed in withdrawing alcoholics compared with control subjects.


Medicine ◽  
2017 ◽  
Vol 96 (51) ◽  
pp. e9237 ◽  
Author(s):  
Shinta Mizuno ◽  
Masatoshi Wakui ◽  
Yujiro Machida ◽  
Naoki Hosoe ◽  
Tadakazu Hisamatsu ◽  
...  

Author(s):  
Mami Ishibashi ◽  
Tomohiro Oiwa ◽  
Takashi Nomura ◽  
Yoshiaki Yoshikawa ◽  
Hironori Niizeki ◽  
...  

2018 ◽  
Vol 5 (4) ◽  
Author(s):  
Arihiro S ◽  
Arai Y ◽  
Matsuura T ◽  
Okayasu I ◽  
Ito S ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document